199 related articles for article (PubMed ID: 23455868)
21. Dabigatran, intracranial hemorrhage, and the neurosurgeon.
Awad AJ; Walcott BP; Stapleton CJ; Yanamadala V; Nahed BV; Coumans JV
Neurosurg Focus; 2013 May; 34(5):E7. PubMed ID: 23634926
[TBL] [Abstract][Full Text] [Related]
22. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
23. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
25. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
[TBL] [Abstract][Full Text] [Related]
27. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.
De Smedt A; De Raedt S; Nieboer K; De Keyser J; Brouns R
Cerebrovasc Dis; 2010; 30(5):533-4. PubMed ID: 20881383
[No Abstract] [Full Text] [Related]
28. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
Dzeshka MS; Lip GY
Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
[TBL] [Abstract][Full Text] [Related]
29. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
30. Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
Kuwauchi S; Watanabe S; Abe K; Yamasaki M; Ito J; Kawazoe K
Ann Thorac Surg; 2013 Nov; 96(5):1863-4. PubMed ID: 24182477
[TBL] [Abstract][Full Text] [Related]
31. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Kate M; Szkotak A; Witt A; Shuaib A; Butcher K
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1351-5. PubMed ID: 24406026
[TBL] [Abstract][Full Text] [Related]
32. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
33. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Siddiqui FM; Qureshi AI
Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
35. Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
Garber ST; Sivakumar W; Schmidt RH
J Neurosurg; 2012 May; 116(5):1093-6. PubMed ID: 22394293
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.
Hohnloser SH; Camm AJ
Europace; 2013 Oct; 15(10):1407-11. PubMed ID: 23954917
[TBL] [Abstract][Full Text] [Related]
37. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
[TBL] [Abstract][Full Text] [Related]
38. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Gulseth MP; Wittkowsky AK; Fanikos J; Spinler SA; Dager WE; Nutescu EA
Pharmacotherapy; 2011 Dec; 31(12):1232-49. PubMed ID: 22122184
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
[TBL] [Abstract][Full Text] [Related]
40. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Kumar R; Smith RE; Henry BL
J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
